Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
Conference Coverage
In favorable intermediate-risk prostate cancer, brachytherapy alone suffices
Publish date:
October 6, 2016
AT ASTRO 2016
op@frontlinemedcom.com
Pages
« first
1
2
Recommended Reading
Study supports extending docetaxel therapy in metastatic castration-resistant prostate cancer
MDedge Hematology and Oncology
Drug combo shows promise for non–clear cell renal cell carcinoma
MDedge Hematology and Oncology
New anticancer drugs linked to increased costs, life expectancy
MDedge Hematology and Oncology
FDA modifies dosage regimen for nivolumab
MDedge Hematology and Oncology
No link between vasectomy, prostate cancer in U.S. cohort
MDedge Hematology and Oncology
10-year follow-up: Localized prostate cancer treatments offer similar efficacy
MDedge Hematology and Oncology
Evaluation of a policy of lymph node retrieval for colon cancer specimens: a quality improvement opportunity
MDedge Hematology and Oncology
A positive attitude in prostate cancer challenges: finding hope and optimism
MDedge Hematology and Oncology
Prostate cancer recurrence rates low with SBRT
MDedge Hematology and Oncology
Hypofractionated RT safe, convenient in low-risk prostate cancer
MDedge Hematology and Oncology
Genitourinary Cancer
All Specialties
